To the Editor The article by Bhaskaran et al, which used a large multicenter cohort of patients with pathogenic/likely pathogenic (P/LP) variants in LMNA-encoded lamin A/C to ascertain the impact of variant location on cardiac outcomes, is welcome. However, the large number of patients with familial partial lipodystrophy type 2 (FPLD2) included in this study raises concerns about the conclusion that tail-domain missense variants are associated with lower risk of major ventricular arrhythmia (VA) and heart failure (HF) events.
JAMA Cardiology published a clinical update in Cardiology on 01 Apr 2026.
The item focuses on Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy.
Review the original article for the full source wording and details.